Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mortality Signal For Pfizer's Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class

Feb 21 2019

• By Emily Hayes

"Uncertainty Ahead” sign on a background of blue sky with clouds

Related Content

AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms

Sep 12 2017

Oral Dosing May Not Be Enough To Win Speedy Adoption Of Pfizer’s RA Pill <em>Xeljanz</em>

Nov 12 2012

Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up

Sep 12 2018

Panel Backs Pfizer’s Tofacitinib For RA, With Narrower Indication

May 10 2012

Lilly's Baricitinib Wins US FDA Panel Thumbs Up For One Of Two Doses

Apr 24 2018

Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects

Jun 03 2018

PIPELINE WATCH – 10 Approvals, Two Breakthroughs And A Refusal To File Letter

Mar 01 2016

Pfizer: Time To Face The Lyrica Pain

Jan 29 2019

AbbVie Soothes Safety Fears With More Upadacitinib RA Data

Jun 07 2018

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

Jun 02 2018

Related Companies

Pfizer Inc.

Eli Lilly and Company

Incyte Corporation

AbbVie Inc.

Gilead Sciences, Inc.

Additional Topics

FDA Regulation Immune Disorders BioPharmaceutical

More from Immunological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window